Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Viatris Inc (VTRS)

Viatris Inc (VTRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Viatris Inc 1000 MYLAN BOULEVARD CANONSBURG PA 15317 USA

www.viatris.com/en P: 724-514-1800

Description:

Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.

Key Statistics

Overview:

Market Capitalization, $K 12,371,124
Enterprise Value, $K 29,510,724
Shares Outstanding, K 1,190,676
Annual Sales, $ 15,427 M
Annual Net Income, $ 54,700 K
Last Quarter Sales, $ 3,663 M
Last Quarter Net Income, $ 113,900 K
EBIT, $ 570,300 K
EBITDA, $ 3,311 M
60-Month Beta 1.13
% of Insider Shareholders 0.26%
% of Institutional Shareholders 79.88%
Float, K 1,187,580
% Float 99.74%
Short Volume Ratio 0.43

Growth:

1-Year Return 13.17%
3-Year Return -33.01%
5-Year Return -40.75%
5-Year Revenue Growth 34.92%
5-Year Earnings Growth -36.03%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.67 on 05/09/24
Next Earnings Date N/A
Earnings Per Share ttm 2.81
EPS Growth vs. Prev Qtr 9.84%
EPS Growth vs. Prev Year -14.10%
Annual Dividend Rate, $ 0.48
Annual Dividend Yield 4.62%
Most Recent Dividend 0.120 on 05/23/24
Next Ex-Dividends Date 05/23/24
Dividend Payable Date 06/14/24
Dividend Payout Ratio 16.82%

VTRS Ratios

Ratio
Price/Earnings ttm 3.70
Price/Earnings forward 3.78
Price/Earnings to Growth N/A
Return-on-Equity % 16.63%
Return-on-Assets % 7.10%
Profit Margin % 0.35%
Debt/Equity 0.90
Price/Sales 0.80
Price/Cash Flow 1.99
Price/Book 0.62
Book Value/Share 16.81
Interest Coverage -1.35

VTRS Dividends

Date Value
05/23/24 $0.1200
03/08/24 $0.1200
11/22/23 $0.1200
08/23/23 $0.1200
05/23/23 $0.1200
03/08/23 $0.1200
11/22/22 $0.1200
08/23/22 $0.1200
05/23/22 $0.1200
02/23/22 $0.1200
11/22/21 $0.1100
08/23/21 $0.1100
05/21/21 $0.1100
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar